By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists agree that INBRX-106's 44% ORR in combination with pembrolizumab is notable but early-stage, with critical uncertainties around durability, control arm ORR, and OS benefit. They express concern about INBX's cash runway and potential dilution.
Risk: INBX's limited cash runway and potential dilution before pivotal trial results.
Opportunity: Potential long-term OS benefit from deeper responses with INBRX-106, if confirmed in Phase 3 trials.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential. Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced on May 11 positive interim results from the randomized, first-line Phase 2 portion of the HexAgon study, with the trial evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab versus pembrolizumab monotherapy in first-line patients with treatment-naïve, PD-L1-positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. It reported that the interim analyses showed that INBRX-106 + pembrolizumab attained a 44.0% confirmed Objective Response Rate. In addition, the responding patients in the combination arm exhibited deeper overall tumor reductions, with the majority attaining target lesion shrinkage that exceeded 50%. Three patients also notably achieved a complete radiographic response.
In a separate development, Inhibrx Biosciences, Inc. (NASDAQ:INBX) received a rating update from Stifel on April 22. The firm lifted the price target on the stock to $300 from $150 and maintained a Buy rating on the shares.
Inhibrx Biosciences, Inc. (NASDAQ:INBX) is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates that were developed through proprietary modular protein engineering platforms. The company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106.
While we acknowledge the potential of INBX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"The positive Phase 2 interim data is a promising clinical milestone, but the stock's valuation is currently disconnected from the harsh reality of the capital-intensive, high-risk nature of independent clinical-stage drug development."
The 44% Objective Response Rate (ORR) for INBRX-106 is admittedly eye-catching in the crowded Head and Neck Squamous Cell Carcinoma (HNSCC) space, where pembrolizumab monotherapy typically struggles to clear 20-25% in broader populations. However, investors must distinguish between Inhibrx Biosciences (INBX) and the legacy Inhibrx entity recently acquired by Sanofi. Following the spin-off, INBX is essentially a 'stub' company. The $300 price target from Stifel is likely factoring in the long-term potential of the legacy pipeline, but liquidity and R&D burn rates remain existential threats. A 44% ORR in a small Phase 2 cohort is a signal, not a cure; the path to pivotal trial success and eventual commercialization is fraught with regulatory hurdles and high capital requirements.
The '10x potential' narrative ignores that clinical-stage biotech stocks often dilute shareholders into oblivion through secondary offerings long before a drug reaches the market.
"N/A"
[Unavailable]
"A 44% ORR is encouraging but insufficient to justify 10x upside claims without OS data, durable response evidence, and context on the control arm's efficacy."
The 44% ORR in INBRX-106 + pembrolizumab is solid for first-line HNSCC, but the article conflates interim Phase 2 data with commercial viability. Critical unknowns: durability of response (how long do those 44% stay in remission?), the control arm's ORR (44% sounds good until you learn pembrolizumab monotherapy hit 35%—a marginal 9-point lift), and whether this translates to OS (overall survival) benefit, which regulators ultimately care about. The Stifel $300 PT doubling from $150 on interim data alone warrants skepticism; biotech valuations on Phase 2 interim results are notoriously volatile. INBX has a market cap around $1.2B—pricing in massive success already.
If response durability is strong and OS data (due later) confirms the trend, INBRX-106 could be a genuine first-line combination therapy in a large market; Stifel's upgrade may reflect genuine conviction from deep diligence, not hype.
"Interim Phase 2 ORR signals for INBRX-106 are promising but not predictive of Phase 3 success or overall survival, so durability and safety in larger trials are the critical tests for upside."
INBX's interim Phase 2 readout for INBRX-106 with pembrolizumab in first-line PD-L1+ HNSCC shows a 44% confirmed ORR and deeper tumor shrinkage, including complete responses. That signal is notable, but the data likely come from a small, non-definitive cohort typical of early-phase studies, with no OS or long-term durability data disclosed. OX40 agonists carry safety risks and the durability of responses in the combo setting remains uncertain. The article’s 10x upside framing relies on a Phase 3 win and a broad addressable market, which could be far from guaranteed. Investors should demand clarity on safety, durability, and a clear Phase 3 path before extrapolating.
Durability and safety in a larger cohort could turn the signal into a bona fide standout; if Phase 3 confirms benefit, the stock could re-rate meaningfully, making the optimistic setup less risky than it appears.
"The clinical value of INBRX-106 hinges on the depth of response and potential for long-term survival, not just incremental ORR gains."
Claude, your skepticism regarding the 9-point lift is vital, but you're missing the 'tail' effect. In HNSCC, the issue isn't just ORR; it's the depth of response and the potential for durable, long-term survival in patients who fail standard checkpoint inhibitors. If INBRX-106 shows a higher rate of Complete Response (CR) compared to pembro-monotherapy, the OS benefit could be massive. The risk isn't just the data; it's the cash runway required to reach that pivotal readout.
[Unavailable]
"Cash runway + Phase 3 timeline mismatch makes dilution near-certain before efficacy is proven, overshadowing the CR upside."
Gemini's CR depth argument is sound, but we're conflating two separate risks. Yes, deeper responses *could* drive OS benefit—but that's speculative until Phase 3 data lands. The cash runway issue is more immediate and concrete. INBX burned ~$80M annually pre-spin; at current cash, that's ~18 months of runway. A Phase 3 in HNSCC takes 2–3 years minimum. Secondary dilution is nearly inevitable before any pivotal readout, which will crater per-share value regardless of efficacy. That's the real tail risk.
"Even with a durable Phase 2 signal, the real risk is rapid dilution or expensive financing to reach Phase 3, which could erode upside far more than interim ORR data suggests."
You rightly flag 18 months of runway and likely dilution—but the bigger tail risk is financial engineering post-spin. If Phase 2 durability is signaling but there’s no clear OS bump, investors may demand a partner or license deal, which could occur at a fraction of the upside. The 'stub' narrative isn't priced in risk; even with a Phase 3, milestones and burn could accelerate, crater the cap table, and derail upside.
The panelists agree that INBRX-106's 44% ORR in combination with pembrolizumab is notable but early-stage, with critical uncertainties around durability, control arm ORR, and OS benefit. They express concern about INBX's cash runway and potential dilution.
Potential long-term OS benefit from deeper responses with INBRX-106, if confirmed in Phase 3 trials.
INBX's limited cash runway and potential dilution before pivotal trial results.